@Blueberrymgmnt Think weve debated this but the article precedes the POINT-Avacta RNS. Clearly stating CanSeek brings PNT2004. IMO this was choreographed with Avacta RNS to follow, and 2004 was already well in flight. Bachovchin co-founded POINT so expect he had early input into the science.2/2

@Blueberrymgmnt Agree - his name is on multiple Avacta patents as one of the inventors of the IP.

This gives me even greater confidence that Lilly is looking a not just proprietary POINT tech but also that of partners with whom POINT signed deals. IMO Lilly knows exactly what #AVCT is up to + it’s increasingly likely they will be in the pack sniffing round its tech.5/5

@Littleboyblue75 @nickkaulbach Not to be a pedant but if they are discussing with BP but they cant agree to meet CC’s valuation for the business, is that not then TO discussions, which you earlier called bullshit + said simply isn’t happening?

@Littleboyblue75 @nickkaulbach Saying in absolute terms that BP isn’t discussing TO options is absurd. I think there is a fair chance they are but it’s not definite. We don’t have enough information. By your logic any co w/o a failed TO attempt to prove otherwise is not subject to any TO activity. 3/3

@nickkaulbach $LLY were a bit shaky with their weightloss/diabetes drugs late last year. They need to diversify or see a similar reliance to Merck + Keytruda. So arguably need to make hay while the sunshines. Others in the pack need to stay competitive + find their Keytruda or Enhertu. 2/2

@Tom_The_Bomb__ @avacta Thrust, the new US-based PR/IR co, is also noted at the investor and communication contact in the RNS. So increasingly US centric.

@Tom_The_Bomb__ @Ian07594592 @Livinginthesurf While it’s hard to dispute that a BP co buying a $1bn biotech for $10bn, is going to be easier to rationale than a $200m biotech for $10bn, I am in the “Pharma pays what the tech is worth” camp. I expect multiple BP think it’s worth a lot + offer accordingly.

@Tom_The_Bomb__ @Ian07594592 @Livinginthesurf Dont dispute CLN is a drag but IMO, it’s a bigger set of issues; meaning data, trial progress + new IP, which has great worth, can’t add value to the MCAP. Which is why I think mgmt is looking beyond incremental “inflection points” to major strategic moves to cement value.2/2